<DOC>
	<DOCNO>NCT02258282</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy etanercept patient psoriasis unsatisfactory response traditional DMARDs .</brief_summary>
	<brief_title>Safety Efficacy Etanercept Patients With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>plaque psoriasis show unsatisfactory response traditional DMARDs 18 75 year old PGA 3 Day 0 BSA 3 % Day 0 psoriasis severe enough eligible systemic therapy willing use effective method contraception least 30 day Day 0 least 1 month last drug administration ; capable give informed consent normal non clinically significant chest Xray within 6 month prior Day 0 negative Purified Protein Derivative ( PPD ) Quantiferon TB Gold test within 90 day prior Day 0 female patient childbearing potential negative serum pregnancy test patient able start etanercept per approved product monograph use topical steroid , topical tar preparation , antipsoriatic preparation within two week prior Day 0 study period presence erythrodermic , pustular guttate psoriasis significant infection within 30 day prior Day 0 receive investigational drug within four week prior screen study period treat systemic antipsoriatic drug steroid , retinoids , cyclosporine , PUVA therapy methotrexate within four week prior Day 0 study period receive systemic antibiotic within four week prior Day 0 treat ultraviolet light therapy ( UVB , nbUVB ) within two week prior Day 0 study period use infliximab within 14 day Day 0 study period use biologic agent treatment psoriasis besides etanercept 8 week prior Day 0 study period allergic reaction infliximab unstable serious medical condition define investigator presence significant medical condition might cause study detrimental patient uncontrolled severe comorbidities poorly control diabetes mellitus , NYHA class III IV heart failure , history myocardial infarction cerebrovascular accident transient ischemic attack within three month screen visit ; unstable angina pectoris uncontrolled hypertension , oxygendependent severe pulmonary disease know seropositivity HIV virus history immunosuppressive disease active chronic Hepatitis B C mycobacterial disease , patient chest XRay suggestive tuberculosis patient take antituberculosis medication know hypersensitivity etanercept one component receive live attenuated vaccine within 12 week prior Day 0 plan receive one study current pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>